Kempner Capital Management Inc. Acquires 107,648 Shares of GSK plc (NYSE:GSK)

Kempner Capital Management Inc. grew its stake in shares of GSK plc (NYSE:GSK) by 142.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 183,080 shares of the pharmaceutical company’s stock after purchasing an additional 107,648 shares during the quarter. GSK makes up 3.4% of Kempner Capital Management Inc.’s portfolio, making the stock its 7th largest holding. Kempner Capital Management Inc.’s holdings in GSK were worth $6,192,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Mesirow Financial Investment Management Inc. grew its holdings in GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after buying an additional 323 shares in the last quarter. Rehmann Capital Advisory Group increased its position in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after acquiring an additional 332 shares during the period. Investment Partners Asset Management Inc. boosted its position in GSK by 2.3% during the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after acquiring an additional 344 shares during the period. Finally, Bond & Devick Financial Network Inc. grew its stake in shares of GSK by 5.4% in the third quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock worth $320,000 after purchasing an additional 400 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

GSK opened at $35.35 on Friday. The business has a fifty day simple moving average of $34.01 and a 200-day simple moving average of $37.73. The firm has a market cap of $73.27 billion, a PE ratio of 22.96, a P/E/G ratio of 1.37 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.